These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 27259561)
1. Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma. Roife D; Dai B; Kang Y; Perez MVR; Pratt M; Li X; Fleming JB Clin Cancer Res; 2016 Dec; 22(24):6021-6030. PubMed ID: 27259561 [TBL] [Abstract][Full Text] [Related]
2. Quantification of fluorophore distribution and therapeutic response in matched in vivo and ex vivo pancreatic cancer model systems. Solanki A; King D; Thibault G; Wang L; Gibbs SL PLoS One; 2020; 15(2):e0229407. PubMed ID: 32097436 [TBL] [Abstract][Full Text] [Related]
4. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Ulrich-Pur H; Raderer M; Verena Kornek G; Schüll B; Schmid K; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Scheithauer W Br J Cancer; 2003 Apr; 88(8):1180-4. PubMed ID: 12698181 [TBL] [Abstract][Full Text] [Related]
5. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study. Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161 [TBL] [Abstract][Full Text] [Related]
6. Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing. Knoll L; Hamm J; Stroebel P; Jovan T; Goetze R; Singh S; Hessmann E; Ellenrieder V; Ammer-Herrmenau C; Neesse A Neoplasia; 2024 Jul; 53():101002. PubMed ID: 38744194 [TBL] [Abstract][Full Text] [Related]
7. Chronic nicotine inhibits the therapeutic effects of gemcitabine on pancreatic cancer in vitro and in mouse xenografts. Banerjee J; Al-Wadei HA; Schuller HM Eur J Cancer; 2013 Mar; 49(5):1152-8. PubMed ID: 23146955 [TBL] [Abstract][Full Text] [Related]
8. Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Cham KK; Baker JH; Takhar KS; Flexman JA; Wong MQ; Owen DA; Yung A; Kozlowski P; Reinsberg SA; Chu EM; Chang CW; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Yapp DT; Ng SS Br J Cancer; 2010 Jun; 103(1):52-60. PubMed ID: 20531411 [TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526 [TBL] [Abstract][Full Text] [Related]
11. Gemcitabine resistance in pancreatic cancer: picking the key players. Kim MP; Gallick GE Clin Cancer Res; 2008 Mar; 14(5):1284-5. PubMed ID: 18316544 [No Abstract] [Full Text] [Related]
12. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors. Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368 [TBL] [Abstract][Full Text] [Related]
13. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352 [TBL] [Abstract][Full Text] [Related]
14. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models. Pham NA; Tsao MS; Cao P; Hedley DW Pancreas; 2007 Oct; 35(3):e16-26. PubMed ID: 17895832 [TBL] [Abstract][Full Text] [Related]
15. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621 [TBL] [Abstract][Full Text] [Related]
16. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007 [TBL] [Abstract][Full Text] [Related]
17. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer. Wolfe AR; Robb R; Hegazi A; Abushahin L; Yang L; Shyu DL; Trevino JG; Cruz-Monserrate Z; Jacob JR; Palanichamy K; Chakravarti A; Williams TM Clin Cancer Res; 2021 Jan; 27(2):554-565. PubMed ID: 33087331 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation. Ju HQ; Gocho T; Aguilar M; Wu M; Zhuang ZN; Fu J; Yanaga K; Huang P; Chiao PJ Mol Cancer Ther; 2015 Mar; 14(3):788-98. PubMed ID: 25527634 [TBL] [Abstract][Full Text] [Related]
19. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma. Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745 [TBL] [Abstract][Full Text] [Related]
20. Xenografts Derived From Patients' Ascites Recapitulate the Gemcitabine Resistance Observed in Pancreatic Cancer Patients. Machinaga A; Hori Y; Shimizu K; Okahara K; Yanagita E; Miyoshi M; Itoh T; Sasai K Pancreas; 2019; 48(10):1294-1302. PubMed ID: 31688592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]